Zielinski C C, Stuller I, Dorner F, Pötzi P, Müller C, Eibl M M
Cancer. 1986 Oct 15;58(8):1648-52. doi: 10.1002/1097-0142(19861015)58:8<1648::aid-cncr2820580812>3.0.co;2-e.
The antibody response after vaccination against tick-borne encephalitis (TBE) was studied in patients with breast cancer. Although sex- and age-matched control persons produced high titers of anti-TBE antibodies 2 to 4 weeks after the second of two consecutive vaccinations, patients with breast cancer who were first vaccinated after the start of adjuvant chemotherapy consisting of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) failed to do so. The lack of anti-TBE antibody production was found not only in patients under CMF chemotherapy, but also in those primarily vaccinated 6 to 12 months after the termination of CMF treatment. Patients with breast cancer who had been vaccinated either before or after the onset of disease, but before the initiation of chemotherapy, were shown to have developed significant anti-TBE antibody titers which persisted throughout the course of adjuvant treatment and could be boostered by revaccination during the course of CMF administration. The authors conclude that patients with breast cancer undergoing adjuvant chemotherapy experience a serious and prolonged defect in primary antibody production, whereas secondary immune responses remain unimpaired.
对乳腺癌患者接种蜱传脑炎（TBE）疫苗后的抗体反应进行了研究。尽管年龄和性别匹配的对照者在连续两次接种中的第二次接种后2至4周产生了高滴度的抗TBE抗体，但在开始使用环磷酰胺、甲氨蝶呤和5-氟尿嘧啶（CMF）进行辅助化疗后首次接种的乳腺癌患者却未能产生这种抗体。不仅在接受CMF化疗的患者中发现缺乏抗TBE抗体产生，在CMF治疗结束后6至12个月首次接种疫苗的患者中也发现了这一情况。在疾病发作之前或之后但在化疗开始之前接种过疫苗的乳腺癌患者显示产生了显著的抗TBE抗体滴度，这些滴度在整个辅助治疗过程中持续存在，并且在CMF给药过程中通过再次接种可以得到增强。作者得出结论，接受辅助化疗的乳腺癌患者在初次抗体产生方面经历了严重且持久的缺陷，而二次免疫反应仍未受损。
